Samsung Bioepis Co., Ltd. announced today new data supporting consistent efficacy of SB16 (OBODENCE ®1), a biosimilar to Prolia 2 (denosumab) across patient subgroups compared to the reference ...
A growing body of research shows that diabetes can be stratified into five different subgroups. Researchers at Lund ...
Pegcetacoplan treatment led to proteinuria reduction and eGFR stabilization across important subgroups with C3 glomerulopathy and IC-MPGN. Pegcetacoplan induces a clinically meaningful ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results